Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

over existing therapeutic approaches for Crohn's disease by potentially offering reduced side effects and convenient oral dosing to patients. Traficet-EN is being developed under a strategic alliance with GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD).

About Crohn's Disease

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. It is estimated that the disease affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups characterized by intense symptoms, interspersed with periods of relative remission where symptoms decrease or disappear. As Crohn's disease is a chronic condition, patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few options beyond surgery.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, also a CCR9 antagonist, is in a Phase I clinical trial
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... LAUSANNE , Switzerland , September ... Genetics, leader européen de la médecine basée sur les ... son premier contrat avec le National Health Service au ... Cela fait suite à une forte hausse de la ... cliniques émanant des laboratoires et hôpitaux en Allemagne, en ...
(Date:9/12/2014)...  WellStar Paulding Hospital is the first hospital in ... in the U.S. to offer a new, innovative procedure ... System, Paulding Hospital is on the cutting edge of ... Inspire Therapy offers relief for moderate to ... to use traditional treatments, like Continuous Positive Airway Pressure ...
(Date:9/12/2014)... , Sept. 12, 2014 ... of the "Global Medical Technologies Market 2014-2018" ... Medical technology is a collective term for software ... to ensure good health. The Global Medical Technologies ... and respiratory technology, In vitro diagnostics technology, dental ...
Breaking Medicine Technology:Sophia Genetics annonce son premier contrat avec le National Health Service britannique et un grand laboratoire turc, élargissant ainsi sa clientèle européenne 2WellStar Pioneers New Sleep Apnea Treatment 2Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 2Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 3
... Transgenomic, Inc. (OTC/BB: TBIO) today announced the ... Results and Business Update Conference CallWhen: , Thursday, August ... How: , Live over the Internet -- Simply log ... Investor Relations, 402-452-5400To access the call via telephone, call ...
... 11, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... pharmaceutical and biotechnology research and development outsourcing company, today ... two multi-staged projects in its biologics division, which portends ... The initial milestones were achieved for two oncology ...
Cached Medicine Technology:Transgenomic to Hold Second Quarter Financial Results Conference Call Today 2ShangPharma's Biologics Division Announces Accelerated Achievement of Milestones for Two Multi-Stage Projects 2
(Date:9/14/2014)... September 14, 2014 School requires that children ... requires that they be screened only for far vision when ... feet away. When their eyes do not track effectively ... they will, at best, avoid reading; at worst, they ... their ability to learn. Children who cannot see cannot ...
(Date:9/13/2014)... New York, NY (PRWEB) September 13, 2014 ... Maroon 5 concert tickets. This beloved pop-rock group ... released V, their fifth studio album. Fans of the group ... released their previous album. If fans were excited yet about ... to know that Maroon 5 has announced a massive worldwide ...
(Date:9/13/2014)... York (PRWEB) September 13, 2014 Stryker ... of the 2012 Rejuvenate and ABG II Modular-Neck Hip ... underway in New Jersey’s Bergen County Superior Court, Bernstein ... issued by the Court on September 10th, 2,097 cases ... increase of 33 filings since the Court issued its ...
(Date:9/13/2014)... Hastings and Hastings, a discount Phoenix ... of dedicated client friendly legal services. As an Arizona ... combined experience, Hastings and Hastings offers aggressively discounted personal ... more impressive is the fact that this firm began ... located across the entire state of Arizona. This provides ...
(Date:9/13/2014)... Deaf Awareness falls on the last full week in September. ... a week-long celebration with events and activities. All events use ... of communication. Voice interpretation will be provided upon request. , ... yoga class, a financial seminar and a sign language class ... is as follows: , BALTIMORE'S BIGGEST ASL CLASS, TUESDAY, SEPTEMBER ...
Breaking Medicine News(10 mins):Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 2Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 3Health News:Stryker Hip Lawsuit News: Rejuvenate and ABG II Hip Lawsuit Filings Near 2,100 in New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: Rejuvenate and ABG II Hip Lawsuit Filings Near 2,100 in New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Hastings & Hastings Reports Reaching 30 Years Of Dedicated Client Friendly Legal Services 2Health News:Hastings & Hastings Reports Reaching 30 Years Of Dedicated Client Friendly Legal Services 3Health News:Baltimore Nonprofit Celebrates Deaf Awareness Week 2Health News:Baltimore Nonprofit Celebrates Deaf Awareness Week 3
... , THURSDAY, Jan. 20 (HealthDay News) -- Emotions can ... products such as airbags, vaccines and smoke detectors, researchers ... they learn that a safety product may carry certain ... airbags sometimes injure or kill. But just because these ...
... HealthDay Reporter , THURSDAY, Jan. 20 (HealthDay News) -- ... the help of aides Wednesday, bodes well for her ... will be moved Friday, just 13 days after a ... University Medical Center in Tucson indicate that the Arizona ...
... paper published Jan. 21 in the journal Science , ... Blossom Damania, PhD, has shown for the first time that ... a key molecule involved in the human immune response. ... Kenan, Jr. Distinguished Professor, Jenny Ting, PhD. First ...
... support system in the first year after diagnosis are less ... to new research from Vanderbilt-Ingram Cancer Center (VICC) and the ... author Meira Epplein, Ph.D., assistant professor of Medicine at VICC, ... of Clinical Oncology. Patients in the study ...
... have found that when patients and providers speak ... better health care quality. The findings were based ... Johnson Foundation,s Latino Health Survey. Understanding the ... important public health implications for providing services in ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, ... be behaving very differently depending on what side of ... example, H1N1 ("swine") flu still predominated in Britain, where 112 ... flu patients, and some doctors report running out of vaccine, ...
Cached Medicine News:Health News:Emotions May Sidetrack Use of Safety Devices 2Health News:Rep. Giffords Standing Up, Set to Begin Rehab Friday 2Health News:Rep. Giffords Standing Up, Set to Begin Rehab Friday 3Health News:Viral protein mimic keeps immune system quiet 2Health News:Strong social ties benefit breast cancer patients 2Health News:Speaking the same language means better health care quality, Wayne State University study finds 2Health News:H1N1 Flu Is Raging in Britain; Could U.S. Be Next? 2Health News:H1N1 Flu Is Raging in Britain; Could U.S. Be Next? 3
PDA-version of the leading portable drug reference....
PDA formatted guide containing outlines and detailed information on the diagnosis and treatment of HIV infection and AIDS....
PDA application contains 15,000+ ICD-9-CM Diagnosis codes....
Information on diagnosis and management of 500 common or important medical and surgical disorders....
Medicine Products: